Back to Search
Start Over
A possible role of thrombinâactivatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
- Source :
- Nephrology Dialysis Transplantation; Aug2001, Vol. 16 Issue 8, p1692-1696, 5p
- Publication Year :
- 2001
-
Abstract
- Background. Cardiovascular disease (CVD) is a major cause of death in renal transplant recipients (RTR). Suppression of fibrinolysis plays a role in the progression of atherosclerosis. Accelerated progression of atherosclerosis and fibrinolytic system suppression has been observed in RTR. Despite many years of intensive research, the reason for impaired fibrinolysis in this patient population is not fully understood. Thrombinâactivatable fibrinolysis inhibitor (TAFI) is a recently discovered glycoprotein combining coagulation and fibrinolysis. This study was conducted to evaluate concentrations of TAFI, markers of thrombin generation, endothelial injury, and some standard laboratory parameters in RTR receiving triple immunosuppressive drug regimen. [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 09310509
- Volume :
- 16
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Nephrology Dialysis Transplantation
- Publication Type :
- Academic Journal
- Accession number :
- 44429963
- Full Text :
- https://doi.org/10.1093/ndt/16.8.1692